Colorectal Cancer Immunotherapy: Options and Strategies

Nor Adzimah Johdi, Nur Fazilah Sukor, Nor Adzimah Johdi, Nur Fazilah Sukor

Abstract

Colorectal cancer is the third most common cancer in the world with increasing incidence and mortality rates globally. Standard treatments for colorectal cancer have always been surgery, chemotherapy and radiotherapy which may be used in combination to treat patients. However, these treatments have many side effects due to their non-specificity and cytotoxicity toward any cells including normal cells that are growing and dividing. Furthermore, many patients succumb to relapse even after a series of treatments. Thus, it is crucial to have more alternative and effective treatments to treat CRC patients. Immunotherapy is one of the new alternatives in cancer treatment. The strategy is to utilize patients' own immune systems in combating the cancer cells. Cancer immunotherapy overcomes the issue of specificity which is the major problem in chemotherapy and radiotherapy. The normal cells with no cancer antigens are not affected. The outcomes of some cancer immunotherapy have been astonishing in some cases, but some which rely on the status of patients' own immune systems are not. Those patients who responded well to cancer immunotherapy have a better prognostic and better quality of life.

Keywords: FDA; T-cells; antibodies; colorectal carcinoma; cytokines; immunotherapy; treatments.

Copyright © 2020 Johdi and Sukor.

Figures

FIGURE 1
FIGURE 1
Monoclonal antibodies in cancer. Monoclonal antibodies (mAbs) such as Cetuximab are designed to target tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs) that are abundant in cancer cells surface. The signals produced by receptor activities mediated immune cells toward malignant sites thus produced immune responses that lead to cell death to eradicate the tumor.
FIGURE 2
FIGURE 2
Deactivated (A) and activated (B) T cell-based on immune checkpoint inhibitors mechanism. During resting of T cell (deactivated T cell), CTLA4 and PD1 receptors on T cell surface binds to CD80 and CD86 on the antigen-presenting cell (APC) such as dendritic cell and PDL-1 and PDL-2 on cancer cell, respectively, while T cell receptor (TCR) binds to major histocompatibility complex (MHC) with the presence of peptide. Thus, no immune response triggered to kill cancer cells. T cells will only be activated with the presence of blockade or inhibitor on CTLA4 and PD1 receptors. Hence, a CTLA4 inhibitor known as Ipilimumab and PD1 inhibitor of Nivolumab functioned to block those receptors and elicit immune response thus leading to the apoptosis of cancer cells.
FIGURE 3
FIGURE 3
CAR-T cells approach to treating cancer. T cells were firstly isolated either from the patient itself or HLA matched donor through apheresis. Next, the cells were cultured and a genetically modified chimeric antigen receptor (CAR) was inserted into it and these T cells are now known as CAR-T cells. This modification is necessary to enhance T cells’ ability to recognize tumor-associated antigens (TAAs) such as CD19 and avoid the major histocompatibility complex class I (MHC I) restriction recognition on the cancer cell. Upon binding, FAS ligand (FASL) and TNF-related apoptosis-inducing ligand (TRAIL) promotes cytotoxicity by releasing effector cytokines and lead to cancer cell apoptosis.

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2018) 68:394–424. 10.3322/caac.21492
    1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: Cancer Today. (2019). Available online at: (accessed September 21, 2019).
    1. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. (2017) 67:177–93. 10.3322/caac.21395
    1. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. (2016) 66:683–91. 10.1136/gutjnl-2015-310912
    1. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. (2012) 23:2479–516. 10.1093/annonc/mds236
    1. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. (2014) 25(Suppl. 3):iii1–9. 10.1093/annonc/mdu260
    1. Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: A JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. (2018) 29:44–70. 10.1093/annonc/mdx738
    1. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. (2016) 27:1386–422. 10.1093/annonc/mdw235
    1. Bonjer HJ, Deijen CL, Abis GA, Cuesta MA, Van der Pas MHGM, De Lange-de Klerk ESM, et al. A randomized trial of laparoscopic versus open surgery for rectal cancer. N Engl J Med. (2015) 372:1324–32. 10.1056/NEJMoa1414882
    1. MacFarlane JK, Ryall RDH, Heald RJ. Mesorectal excision for rectal cancer. Lancet. (1993) 341:457–60. 10.1016/0140-6736(93)90207-W
    1. Park SC, Sohn DK, Kim MJ, Chang HJ, Han KS, Hyun JH, et al. Phase II clinical trial to evaluate the efficacy of transanal endoscopic total mesorectal excision for rectal cancer. Dis Colon Rectum. (2018) 61:554–60. 10.1097/DCR.0000000000001058
    1. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. (2019) 0:1–23. 10.3322/caac.21565
    1. Garg MB, Lincz LF, Adler K, Scorgie FE, Ackland SP, Sakoff JA. Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis. Br J Cancer. (2012) 107:1525–33. 10.1038/bjc.2012.421
    1. González-Perera I, Gutiérrez-Nicolás F, Nazco-Casariego GJ, Ramos-Diaz R, Hernández-San GR, Pérez-Pérez JA, et al. 5-fluorouracil toxicity in the treatment of colon cancer associated with the genetic polymorphism 2846 A>G (rs67376798). J Oncol Pharm Pract. (2017) 23:396–8. 10.1177/1078155216647202
    1. Ogura A, Konishi T, Cunningham C, Garcia-Aguilar J, Iversen H, Toda S, et al. Neoadjuvant (Chemo)radiotherapy with total mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes: results of the multicenter lateral node study of patients with low cT3/4 rectal cancer. J Clin Oncol. (2018) 37:33–43. 10.1200/JCO
    1. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. (2013) 14:1014–22. 10.1038/ni.2703
    1. Marcus A, Gowen BG, Thompson TW, Iannello A, Ardolino M, Deng W, et al. Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol. (2014) 122:91–128. 10.1016/B978-0-12-800267-4.00003-1
    1. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. (2011) 29:235–71. 10.1146/annurev-immunol-031210-101324
    1. Im A, Pavletic SZ. Immunotherapy in hematologic malignancies: past, present, and future. J Hematol Oncol. (2017) 10:1–10. 10.1186/s13045-017-0453-8
    1. Nixon NA, Blais N, Ernst S, Kollmannsberger C, Bebb G, Butler M, et al. Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges. Curr Oncol. (2018) 25:e373–84. 10.3747/co.25.3840
    1. Fehleisen F. Ueber die züchtung der erysipelkokken auf künstlichem nåhrboden und ihre uebertragbarkeit auf den menschen. Dtsch Med Wochenschr. (1882) 8:553–4. 10.1055/s-0029-1196806
    1. Busch W. Aus der sitzung der medicinischen section vom 13 November 1867. Berlin Klin Wochenschr. (1868) 5:137.
    1. Coley WB. II. Contribution to the knowledge of sarcoma. Ann Surg. (1891) 14:199–220. 10.1097/00000658-189112000-00015
    1. McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J. (2006) 26:154–8.
    1. Nikolaou M, Nikolaou G, Digklia A, Pontas C, Tsoukalas N, Kyrgias G, et al. Immunotherapy of cancer: Developments and reference points, an unorthodox approach. Integr Cancer Ther. (2019) 18:1–10. 10.1177/1534735419827090
    1. Coley WB. The treatment of inoperable sarcoma by bacterial toxins (The mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc R Soc Med. (1910) 3:1–48. 10.1177/003591571000301601
    1. Dobosz P, Dzieciątkowski T. The intriguing history of cancer immunotherapy. Front Immunol. (2019) 10:2965. 10.3389/fimmu.2019.02965
    1. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res. (1970) 13:1–27. 10.1159/000386035
    1. Burnet M. Immunological factors in the process of carcinogenesis. Br Med Bull. (1964) 20:154–8. 10.1093/oxfordjournals.bmb.a070310
    1. Klein G, Sjogren HO, Klein E, Hellstrom KE. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. (1960) 20:1561–72.
    1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc London Ser B Biol Sci. (1957) 147:258–67. 10.1098/rspb.1957.0048
    1. Graham JB, Graham RM. The effect of vaccine on cancer patients. Surg Gynecol Obstet. (1959) 109:131–8. 10.1097/00006534-195911000-00016
    1. Miller JFAP, Mitchell GF, Weiss NS. Cellular basis of the immunological defects in thymectomized mice. Nature. (1967) 214:992–7. 10.1038/214992a0
    1. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice: I. Morphology, quantitation, tissue distribution. J Exp Med. (1973) 137:1142–62. 10.1084/jem.137.5.1142
    1. Kiessling R, Klein E, Wigzell H. Natural killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol. (1975) 5:112–7. 10.1002/eji.1830050208
    1. Kiessling R, Klein E, Pross H, Wigzell H. Natural killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol. (1975) 5:117–21. 10.1002/eji.1830050209
    1. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. (1975) 256:495–7. 10.1038/256495a0
    1. Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, et al. A new member of the immunoglobulin superfamily-CTLA-4. Nature. (1988) 328:267–70. 10.1038/328267a0
    1. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. (1997) 90:2188–95.
    1. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. JNCI J Natl Cancer Inst. (1993) 85:622–32. 10.1093/jnci/85.8.622
    1. Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. (2011) 17:3520–6. 10.1158/1078-0432.CCR-10-3126
    1. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. (2010) 363:411–22. 10.1056/NEJMoa1001294
    1. Andtbacka RHI, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. (2015) 33:2780–8. 10.1200/JCO.2014.58.3377
    1. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N Engl J Med. (2017) 377:2531–44. 10.1056/NEJMoa1707447
    1. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. (2019) 380:45–56. 10.1056/NEJMoa1804980
    1. Guo ZS. The 2018 Nobel Prize in medicine goes to cancer immunotherapy (editorial for BMC cancer). BMC Cancer. (2018) 18:1086. 10.1186/s12885-018-5020-3
    1. Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buque A, Senovilla L, Baracco EE, et al. Classification of current anticancer immunotherapies. Oncotarget. (2014) 5:12472–508. 10.18632/oncotarget.2998
    1. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov. (2003) 2:52–62. 10.1038/nrd984
    1. Köhler G, Milstein C. Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur J Immunol. (1976) 6:511–9. 10.1002/eji.1830060713
    1. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. (1985) 228:1315–7. 10.1126/science.4001944
    1. Kurosawa K, Lin W, Ohta K. Chimeric antibodies. Methods Mol Biol. (2014) 1060:139–48. 10.1007/978-1-62703-586-6_8
    1. Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. (2020) 27:1–30. 10.1186/s12929-019-0592-z
    1. Kettleborough CA, Saldanha J, Heath VJ, Morrison CJ, Bendig MM. Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng. (1991) 4:773–83. 10.1093/protein/4.7.773
    1. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJT. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. (2010) 9:325–38. 10.1038/nrd3003
    1. Lipman NS, Jackson LR, Trudel LJ, Weis-Garcia F. Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources. ILAR Journal. (2005) 46:258–68. 10.1093/ilar.46.3.258
    1. Bubeník J, Barešová M, Viklický V, Jakoubková J, Sainerová H, Donner J. Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. Int J Cancer. (1973) 11:765–73. 10.1002/ijc.2910110327
    1. Hollinshead A, Elias EG, Arlen M, Buda B, Mosley M, Scherrer J. Specific active immunotherapy in patients with adenocarcinoma of the colon utilizing tumor-associated antigens (TAA). A phase I clinical trial. Cancer. (1985) 56:480–9. 10.1002/1097-0142(19850801)56:;2-2
    1. Dickinson JP, Caspary EA, Field EJ. A common tumour specific antigen. Br J Cancer. (1973) 27:99–105. 10.1038/bjc.1973.13
    1. Speetjens FM, Kuppen PJK, Welters MJP, Essahsah F, Van Den Brink AMEGV, Lantrua MGK, et al. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res. (2009) 15:1086–95. 10.1158/1078-0432.CCR-08-2227
    1. Alatrash G, Crain AK, Molldrem JJ. Tumor-Associated Antigens. Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation. Amsterdam: Elsevier; (2019). p. 107–25. 10.1016/B978-0-12-812630-1.00007-4
    1. Cloosen S, Arnold J, Thio M, Bos GMJ, Kyewski B, Germeraad WTV. Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: implications for self-tolerance and tumor therapy. Cancer Res. (2007) 67:3919–26. 10.1158/0008-5472.CAN-06-2112
    1. Even-Desrumeaux K, Baty D, Chames P. State of the art in tumor antigen and biomarker discovery. Cancers (Basel). (2011) 3:2554–96. 10.3390/cancers3022554
    1. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. (2002) 188:22–32. 10.1034/j.1600-065X.2002.18803.x
    1. Kerkar SP, Wang ZF, Lasota J, Park T, Patel K, Groh E, et al. MAGE-A is more highly expressed than NY-ESO-1 in a systematic immunohistochemical analysis of 3668 cases. J Immunother. (2016) 39:181–7. 10.1097/CJI.0000000000000119
    1. Yanagi T, Nagai K, Shimizu H, Matsuzawa SI. Melanoma antigen A12 regulates cell cycle via tumor suppressor p21 expression. Oncotarget. (2017) 8:68448–59. 10.18632/oncotarget.19497
    1. Santha Kumara HMC, Grieco MJ, Caballero OL, Su T, Ahmed A, Ritter E, et al. MAGE-A3 is highly expressed in a subset of colorectal cancer patients. Cancer Immun. (2012) 12:1–9.
    1. Nicolazzo C, Raimondi C, Francescangeli F, Ceccarelli S, Trenta P, Magri V, et al. EpCAM-expressing circulating tumor cells in colorectal cancer. Int J Biol Markers. (2017) 32:e415–20. 10.5301/ijbm.5000284
    1. Starzynska T, Marsh PJ, Schofield PF, Roberts SA, Myers KA, Stern PL. Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer. (1994) 69:899–902. 10.1038/bjc.1994.173
    1. Besneux M, Greenshields-Watson A, Scurr MJ, MacLachlan BJ, Christian A, Davies MM, et al. The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: Implications for vaccine design. Cancer Immunol Immunother. (2019) 68:247–56. 10.1007/s00262-018-2266-1
    1. Wang W, Li Y, Zhang X, Jing J, Zhao X, Wang Y, et al. Evaluating the significance of expression of CEA mRNA and levels of CEA and its related proteins in colorectal cancer patients. J Surg Oncol. (2014) 109:440–4. 10.1002/jso.23503
    1. Bright RK, Bright JD, Byrne JA. Overexpressed oncogenic tumor-self antigens. Hum Vaccines Immunother. (2014) 10:3297–305. 10.4161/hv.29475
    1. Liu J, Zhou Q, Xu J, Wang J, Zhang Y. Detection of EGFR expression in patients with colorectal cancer and the therapeutic effect of cetuximab. J BUON. (2016) 21:95–100.
    1. Geng W, Liang W, Fan Y, Ye Z, Zhang L. Overexpression of CCDC34 in colorectal cancer and its involvement in tumor growth, apoptosis and invasion. Mol Med Rep. (2018) 17:465–73. 10.3892/mmr.2017.7860
    1. Wang ZK, Cheng ZW, Chen SJ, Zhu XG, Gu YP, Yang XD, et al. Aberrant expression of Rab1A and its prognostic significance in human colorectal cancer. Eur Rev Med Pharmacol Sci. (2018) 22:4509–17. 10.26355/eurrev_201807_15505
    1. Michaud HA, Eliaou JF, Lafont V, Bonnefoy N, Gros L. Tumor antigen-targeting monoclonal antibody-based immunotherapy: orchestrating combined strategies for the development of long-term antitumor immunity. Oncoimmunology. (2014) 3:e955684. 10.4161/21624011.2014.955684
    1. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. (2012) 12:278–87. 10.1038/nrc3236
    1. Biopharma LLC. BIOPHARMA®: Biopharmaceutical Products in the U.S. and European Markets. (2019). Available online at: (accessed June 26, 2019).
    1. Food and Drug Administration. Resources for Information on Approved Drugs. (2019). Available online at: (accessed June 28, 2019).
    1. European Medicines Agency. (2019). Available online at: (accessed June 28, 2019).
    1. Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: From tumor initiation to metastatic progression. Genes Dev. (2018) 32:1267–84. 10.1101/gad.314617.118
    1. Pardoll D. Cancer and immune system: basic concepts and targets for intervention. Semin Oncol. (2015) 42:523–38. 10.1053/j.seminoncol.2015.05.003
    1. Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and Anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. (2018) 8:86. 10.3389/fonc.2018.00086
    1. Joller N, Kuchroo VK. Tim-3, Lag-3, and TIGIT. Curr Top Microbiol Immunol. (2017) 410:127–56. 10.1007/82_2017_62
    1. Kisielow M, Kisielow J, Capoferri-Sollami G, Karjalainen K. Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells. Eur J Immunol. (2005) 35:2081–8. 10.1002/eji.200526090
    1. Kong Y, Zhu L, Schell TD, Zhang J, Claxton DF, Ehmann WC, et al. T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients. Clin Cancer Res. (2016) 22:3057–66. 10.1158/1078-0432.CCR-15-2626
    1. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. (2002) 415:536–41. 10.1038/415536a
    1. Menter DG, Davis JS, Broom BM, Overman MJ, Morris J, Kopetz S. Back to the colorectal cancer consensus molecular subtype future. Curr Gastroenterol Rep. (2019) 21:1–12. 10.1007/s11894-019-0674-9
    1. Rodriguez-Salas N, Dominguez G, Barderas R, Mendiola M, García-Albéniz X, Maurel J, et al. Clinical relevance of colorectal cancer molecular subtypes. Crit Rev Oncol Hematol. (2017) 109:9–19. 10.1016/j.critrevonc.2016.11.007
    1. Shemirani AI, Haghighi MM, Zadeh SM, Fatemi SR, Taleghani MY, Zali N, et al. Simplified MSI marker panel for diagnosis of colorectal cancer. Asian Pac J Cancer Prev. (2011) 12:2101–4. 10.17179/excli2018-1455
    1. Kawakami H, Zaanan A, Sinicrope FA. Microsatellite instability testing and its role in the management of colorectal cancer. Curr Treat Options Oncol. (2015) 16:1–15. 10.1007/s11864-015-0348-2
    1. Nojadeh JN, Behrouz Sharif S, Sakhinia E. Microsatellite instability in colorectal cancer. EXCLI J. (2018) 17:159–68. 10.17179/excli2017-948
    1. Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. (2016) 15:857–65. 10.1016/j.celrep.2016.03.075
    1. Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. (2018) 36:773–9. 10.1200/JCO.2017.76.9901
    1. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. (1995) 182:459–65. 10.1084/jem.182.2.459
    1. Sanchez-Lockhart M, Rojas AV, Fettis MM, Bauserman R, Higa TR, Miao H, et al. T cell receptor signaling can directly enhance the avidity of CD28 ligand binding. PLoS One (2014) 9:e89263. 10.1371/journal.pone.0089263
    1. Ward SG. CD28: a signalling perspective. Biochem J. (1996) 318:361–77. 10.1042/bj318036
    1. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways similarities, differences, and implications of their inhibition. Am J Clin Oncol Cancer Clin Trials. (2016) 39:98–106. 10.1097/COC.0000000000000239
    1. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. (2001) 19:565–94. 10.1146/annurev.immunol.19.1.565
    1. Egen JG, Kuhns MS, Allison JP. CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nat Immunol. (2002) 3:611–8. 10.1038/ni0702-611
    1. Intlekofer AM, Thompson CB. At the bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol. (2013) 94:25–39. 10.1189/jlb.1212621
    1. Jørgensen N, Persson G, Hviid TVF. The tolerogenic function of regulatory T cells in pregnancy and cancer. Front Immunol. (2019) 10:1–21. 10.3389/fimmu.2019.00911
    1. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA. (2008) 105:14987–92. 10.1073/pnas.0806075105
    1. Lee HT, Lee SH, Heo YS. Molecular interactions of antibody drugs targeting PD-1, PD-L1, and CTLA-4 in immuno-oncology. Molecules. (2019) 4:1–16. 10.3390/molecules24061190
    1. Pernot S, Terme M, Voron T, Colussi O, Marcheteau E, Tartour E, et al. Colorectal cancer and immunity: what we know and perspectives. World J Gastroenterol. (2014) 20:3738–50. 10.3748/wjg.v20.i14.3738
    1. Ishida T, Ishii T, Inagaki A, Yano H, Komatsu H, Iida S, et al. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res. (2006) 66:5716–22. 10.1158/0008-5472.CAN-06-0261
    1. Shinohara T, Taniwaki M, Ishida Y, Kawaichi M, Honjo T. Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics. (1994) 23:704–6. 10.1006/geno.1994.1562
    1. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. (1996) 8:765–72. 10.1093/intimm/8.5.765
    1. Kitano A, Ono M, Yoshida M, Noguchi E, Shimomura A, Shimoi T, et al. Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer. ESMO Open. (2017) 2:e000150. 10.1136/esmoopen-2016-000150
    1. Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, et al. Expression of programmed death 1 ligands by murine T Cells and APC. J Immunol. (2002) 169:5538–45. 10.4049/jimmunol.169.10.5538
    1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. (2012) 12:252–64. 10.1038/nrc3239
    1. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. (2001) 2:261–8. 10.1038/85330
    1. Terawaki S, Chikuma S, Shibayama S, Hayashi T, Yoshida T, Okazaki T, et al. IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol. (2011) 186:2772–9. 10.4049/jimmunol.1003208
    1. Shindo Y, Yoshimura K, Kuramasu A, Watanabe Y, Ito H, Kondo T, et al. Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor. Anticancer Res. (2015) 35:129–36.
    1. Dong Y, Sun Q, Zhang X. PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget. (2017) 8:2171–86. 10.18632/oncotarget.13895
    1. Henick BS, Herbst RS, Goldberg SB. The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. Expert Opin Ther Targets. (2014) 18:1407–20. 10.1517/14728222.2014.955794
    1. Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. (2018) 6:1–18. 10.1186/s40425-018-0316-z
    1. Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, et al. Phase I study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. (2015) 21:4286–93. 10.1158/1078-0432.CCR-14-2607
    1. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csöszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. (2016) 375:1823–33. 10.1056/NEJMoa1606774
    1. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. (2015) 372:2509–20. 10.1056/NEJMoa1500596
    1. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. (2017) 18:1182–91. 10.1016/S1470-2045(17)30422-9
    1. Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, et al. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother. (2008) 31:742–51. 10.1097/CJI.0b013e31818403d5
    1. Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci. (2019) 20:1283. 10.3390/ijms20061283
    1. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med. (1988) 319:1676–80. 10.1056/NEJM198812223192527
    1. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. (2006) 314:126–9. 10.1126/science.1129003
    1. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. (2006) 12(20 Pt 1):6106–15. 10.1158/1078-0432.CCR-06-1183
    1. Lamers CHJ, Willemsen R, Van Elzakker P, Van Steenbergen-Langeveld S, Broertjes M, Oosterwijk-Wakka J, et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood. (2011) 117:72–82. 10.1182/blood-2010-07-294520
    1. Ramos CA, Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther. (2011) 11:855–73. 10.1517/14712598.2011.573476
    1. Wang X, Rivière I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics. (2016) 3:1–7. 10.1038/mto.2016.15
    1. Bishop MR, Maziarz RT, Waller EK, Jäger U, Westin JR, McGuirk JP, et al. Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion. Blood Adv. (2019) 3:2230–6. 10.1182/bloodadvances.2019000151
    1. Pituch KC, Miska J, Krenciute G, Panek WK, Li G, Rodriguez-Cruz T, et al. Adoptive transfer of IL13Rα2-specific chimeric antigen receptor T cells creates a pro-inflammatory environment in glioblastoma. Mol Ther. (2018) 26:986–95. 10.1016/j.ymthe.2018.02.001
    1. Miao H, Choi BD, Suryadevara CM, Sanchez-Perez L, Yang S, De Leon G, et al. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. PLoS One. (2014) 9:e94281. 10.1371/journal.pone.0094281
    1. Lázaro-Gorines R, Ruiz-de-la-Herrán J, Navarro R, Sanz L, Álvarez-Vallina L, Martínez-del-Pozo A, et al. A novel carcinoembryonic antigen (CEA)-targeted trimeric immunotoxin shows significantly enhanced antitumor activity in human colorectal cancer xenografts. Sci Rep. (2019) 9:11680. 10.1038/s41598-019-48285-z
    1. Sadelain M, Rivière I, Riddell S. Therapeutic T cell engineering. Nature. (2017) 545:423–31. 10.1038/nature22395
    1. Tang XY, Sun Y, Zhang A, Hu GL, Cao WW, Dan H, et al. Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol. BMJ Open. (2016) 6:e013904. 10.1136/bmjopen-2016-013904
    1. Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. (2016) 128:1688–700. 10.1182/blood-2016-04-711903
    1. Perica K, Varela JC, Oelke M, Schneck J. Adoptive T cell immunotherapy for cancer. Rambam Maimonides Med J. (2015) 6:e0004. 10.5041/RMMJ.10179
    1. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. (2013) 36:133–51. 10.1097/CJI.0b013e3182829903
    1. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. (2014) 124:188–95. 10.1182/blood-2014-05-552729
    1. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. (2018) 378:439–48. 10.1056/NEJMoa1709866
    1. Pehlivan KC, Duncan BB, Lee DW. CAR-T cell therapy for acute lymphoblastic leukemia: Transforming the treatment of relapsed and refractory disease. Curr Hematol Malig Rep. (2018) 13:396–406. 10.1007/s11899-018-0470-x
    1. Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, et al. Phase 1 Results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. (2017) 25:285–95. 10.1016/j.ymthe.2016.10.020
    1. Magee MS, Abraham TS, Baybutt TR, FlickingerJr JC, Ridge NA, Marszalowicz GP, et al. Human GUCY2C-targeted chimeric antigen receptor (CAR)-expressing T cells eliminate colorectal cancer metastases. Cancer Immunol Res. (2018) 6:509–16. 10.1158/2326-6066.CIR-16-0362
    1. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DAN, Feldman SA, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. (2011) 19:620–6. 10.1038/mt.2010.272
    1. Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, et al. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer. (2017) 5:1–14. 10.1186/s40425-017-0222-9
    1. Zhang BL, Li D, Gong YL, Huang Y, Qin DY, Jiang L, et al. Preclinical evaluation of chimeric antigen receptor–modified T cells specific to epithelial cell adhesion molecule for treating colorectal cancer. Hum Gene Ther. (2019) 30:402–12. 10.1089/hum.2018.229
    1. Deng X, Gao F, Li N, Li Q, Zhou Y, Yang T, et al. Antitumor activity of NKG2D CAR-T cells against human colorectal cancer cells in vitro and in vivo. Am J Cancer Res. (2019) 9:945–58.
    1. Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. (2016) 3:1–7. 10.1038/mto.2016.11
    1. Martinez M, Moon EK. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol. (2019) 10:128. 10.3389/fimmu.2019.00128
    1. Abbasi AM, Chester KA, MacPherson AJ, Boxer GM, Begent RH, Malcolm AD. Localization of CEA messenger RNA by in situ hybridization in normal colonic mucosa and colorectal adenocarcinomas. J Pathol. (1992) 168:405–11. 10.1002/path.1711680411
    1. Zhang C, Wang Z, Yang Z, Wang M, Li S, Li Y, et al. Phase I escalating-dose trial of CAR-T therapy targeting CEA + metastatic colorectal cancers. Mol Ther. (2017) 25:1248–58. 10.1016/j.ymthe.2017.03.010
    1. Chi X, Yang P, Zhang E, Jieyi G, Hui X, Li M, et al. Significantly increased anti−tumor activity of carcinoembryonic antigen−specific chimeric antigen receptor T cells in combination with recombinant human IL−12. Cancer Med. (2019) 8:4753–65. 10.1002/cam4.2361
    1. Wang G, Lu X, Dey P, Deng P, Wu CC, Jiang S, et al. Targeting YAP-dependent MDSC infiltration impairs tumor progression. Cancer Discov. (2016) 6:80–95. 10.1158/-15-0224
    1. Feig C, Jones JO, Kraman M, Wells RJB, Deonarine A, Chan DS, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA. (2013) 110:20212–7. 10.1073/pnas.1320318110
    1. Kershaw MH, Wang G, Westwood JA, Pachynski RK, Tiffany HL, Marincola FM, et al. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther. (2002) 13:1971–80. 10.1089/10430340260355374
    1. Crespo J, Sun H, Welling TH, Tian Z, Zou WT. cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol. (2013) 25:214–21. 10.1016/j.coi.2012.12.003
    1. Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, et al. Current progress in CAR-T cell therapy for solid tumors. Int J Biol Sci. (2019) 15:2548–60. 10.7150/ijbs.34213
    1. Xu Y, Yang Z, Horan LH, Zhang P, Liu L, Zimdahl B, et al. A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release. Cell Discov. (2018) 4:1–13. 10.1038/s41421-018-0066-6
    1. Barrett DM, Grupp SA, June CH. Chimeric antigen receptor– and TCR-Modified T cells enter main street and wall street. J Immunol. (2015) 195:755–61. 10.4049/jimmunol.1500751
    1. Garber K. Driving T-cell immunotherapy to solid tumors. Nat Biotechnol. (2018) 36:215–9. 10.1038/nbt.4090
    1. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. (2009) 114:535–46. 10.1182/blood-2009-03-211714
    1. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. (2011) 29:917–24. 10.1200/JCO.2010.32.2537
    1. Stadtmauer EA, Faitg TH, Lowther DE, Badros AZ, Chagin K, Dengel K, et al. Long−term safety and activity of NY-ESO−1 SPEAR T cells after autologous stem cell transplant for myeloma. Blood Adv. (2019) 3:2022–34. 10.1182/bloodadvances.2019000194
    1. Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. (2013) 122:863–71. 10.1182/blood-2013-03-490565
    1. Kageyama S, Ikeda H, Miyahara Y, Imai N, Ishihara M, Saito K, et al. Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer. Clin Cancer Res. (2015) 21:2268–77. 10.1158/1078-0432.CCR-14-1559
    1. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. (2015) 21:914–21. 10.1038/nm.3910
    1. . (2020). Available online at: (accessed May 31, 2020).
    1. Zhao L, Cao YJ. Engineered T cell therapy for cancer in the clinic. Front Immunol. (2019) 10:2250. 10.3389/fimmu.2019.02250
    1. Thomas S, Prendergast GC. Cancer vaccines: a brief overview. In: Thomas S. editor. Methods in Molecular Biology. (Vol. 1403), New York, NY: Humana Press Inc; (2016). p. 755–61. 10.1007/978-1-4939-3387-7_43
    1. Lollini PL, Cavallo F, Nanni P, Quaglino E. The promise of preventive cancer vaccines. Vaccines. (2015) 3:467–89. 10.3390/vaccines3020467
    1. Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW. Therapeutic cancer vaccines. Adv Cancer Res. (2014) 121:67–124. 10.1016/B978-0-12-800249-0.00002-0
    1. DeMaria PJ, Bilusic M. Cancer vaccines. Hematol Oncol Clin North Am. (2019) 33:199–214. 10.1016/j.hoc.2018.12.001
    1. Barreto L, Csizer Z, Sparkes JD. Evaluation of clinical data in bladder cancer immunotherapy with Connaught BCG (ImmuCyst). Dev Biol Stand. (1992) 77:229–31.
    1. Lamm DL, Blumenstein BA, Crawford, Montie JE, Scardino P, Grossman HB, et al. A randomized trial of intravesical doxorubicin and immunotherapy with Bacille Calmette–Guérin for transitional-cell carcinoma of the bladder. N Engl J Med. (1991) 325:1205–9. 10.1056/NEJM199110243251703
    1. Rentsch CA, Birkhäuser FD, Biot C, Gsponer JR, Bisiaux A, Wetterauer C, et al. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol. (2014) 66:677–88. 10.1016/j.eururo.2014.02.061
    1. Witjes JA, Dalbagni G, Karnes RJ, Shariat S, Joniau S, Palou J, et al. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non–muscle-invasive bladder cancer. Urol Oncol Semin Orig Investig. (2016) 34:484.e19–e25. 10.1016/j.urolonc.2016.05.033
    1. Graddis TJ, McMahan CJ, Tamman J, Page KJ, Trager JB. Prostatic acid phosphatase expression in human tissues. Int J Clin Exp Pathol. (2011) 4:295–306.
    1. Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P. Cancer immunotherapy: sipuleucel-T and beyond. Pharmacotherapy. (2011) 31:813–28. 10.1592/phco.31.8.813
    1. Dores GM, Bryant-Genevier M, Perez-Vilar S. Adverse events associated with the use of sipuleucel-T reported to the US Food and Drug Administration’s adverse event reporting system, 2010-2017. JAMA Netw Open. (2019) 2:e199249. 10.1001/jamanetworkopen.2019.9249
    1. Raman SS, Hecht JR, Chan E. Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety. Immunotherapy. (2019) 11:705–23. 10.2217/imt-2019-0033
    1. Conry RM, Westbrook B, McKee S, Norwood TG. Talimogene laherparepvec: First in class oncolytic virotherapy. Hum Vaccines Immunother. (2018) 14:839–46. 10.1080/21645515.2017.1412896
    1. Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol. (2018) 36:1658–67. 10.1200/JCO.2017.73.7379
    1. Chesney J, Puzanov I, Collichio F, Milhem MM, Hauschild A, Chen L, et al. Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma. Br J Cancer. (2019) 121:417–20. 10.1038/s41416-019-0530-6
    1. Bilusic M, Heery CR, Arlen PM, Rauckhorst M, Apelian D, Tsang KY, et al. Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer Immunol Immunother. (2014) 63:225–34. 10.1007/s00262-013-1505-8
    1. Gulley JL, Arlen PM, Tsang KY, Yokokawa J, Palena C, Poole DJ, et al. Pilot study of vaccination with recombinant CEA-MUC-1-tricom pox viral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res. (2008) 14:3060–9. 10.1158/1078-0432.CCR-08-0126
    1. Kaufman HL, Lenz HJ, Marshall J, Singh D, Garett C, Cripps C, et al. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin Cancer Res. (2008) 14:4843–9. 10.1158/1078-0432.CCR-08-0276
    1. Zhan W, Zhang Z, Zhang Y, Ma J, Wu T, Gu Y, et al. Prognostic value of MAGE-A9 expression in patients with colorectal cancer. Clin Res Hepatol Gastroenterol. (2016) 40:239–45. 10.1016/J.CLINRE.2015.08.005
    1. Zhang QM, He SJ, Shen N, Luo B, Fan R, Fu J, et al. Overexpression of MAGE-D4 in colorectal cancer is a potentially prognostic biomarker and immunotherapy target. Int J Clin Exp Pathol. (2014) 7:3918–27.
    1. Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, et al. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg. (2013) 258:879–86. 10.1097/SLA.0b013e318292919e
    1. Tang CK, Katsara M, Apostolopoulos V. Strategies used for MUC1 immunotherapy: human clinical studies. Expert Rev Vaccines. (2008) 7:963–75. 10.1586/14760584.7.7.963
    1. DiPaola RS, Plante M, Kaufman H, Petrylak DP, Israeli R, Lattime E, et al. A phase I trial of pox PSA vaccines (PROSTVAC®-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOMTM) in patients with prostate cancer. J Transl Med. (2006) 4:1–5. 10.1186/1479-5876-4-1
    1. Hodge JW, McLaughlin JP, Kantor JA, Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine. (1997) 15:759–68. 10.1016/s0264-410x(96)00238-1
    1. Saha A, Chatterjee SK, Foon KA, Celis E, Bhattacharya-Chatterjee M. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen. Cancer Res. (2007) 67:2881–92. 10.1158/0008-5472.CAN-06-3045
    1. Hensel JA, Khattar V, Ashton R, Ponnazhagan S. Recombinant AAV-CEA tumor vaccine in combination with an immune adjuvant breaks tolerance and provides protective immunity. Mol Ther Oncolytics. (2019) 12:41–8. 10.1016/j.omto.2018.12.004
    1. Lamm DL. BCG immunotherapy for transitional-cell carcinoma in situ of the bladder. Oncology (Williston Park). (1995) 9:947–55.
    1. Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res. (2000) 6:2175–82.
    1. Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, et al. Immunotherapy (APC8015, provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a phase 2 trial. Prostate. (2004) 60:197–204. 10.1002/pros.20040
    1. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. (2006) 24:3089–94. 10.1200/JCO.2005.04.5252
    1. Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL, et al. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res. (2011) 17:4558–67. 10.1158/1078-0432.CCR-10-3223
    1. Hu JCC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, et al. A phase I study of OncoVEX GM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. (2006) 12:6737–47. 10.1158/1078-0432.CCR-06-0759
    1. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. (2009) 27:5763–71. 10.1200/JCO.2009.24.3675
    1. Kantoff PW, Schuetz TJ, Blumenstein BA, Michael GL, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. (2010) 28:1099–105. 10.1200/JCO.2009.25.0597
    1. Kantoff PW, Gulley JL, Pico-Navarro C. Revised overall survival analysis of a phase II, randomized, double-blind, controlled study of PROSTVAC in men with metastatic castration-resistant prostate cancer. J Clin Oncol. (2017) 35:124–5. 10.1200/JCO.2016.69.7748
    1. Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, et al. Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. J Clin Oncol. (2019) 37:1051–61. 10.1200/JCO.18.02031
    1. Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, et al. Cytokines in clinical cancer immunotherapy. Br J Cancer. (2019) 120:6–15. 10.1038/s41416-018-0328-y
    1. Rusch T, Bayry J, Werner J, Shevchenko I, Bazhin AV. Immunotherapy as an option for cancer treatment. Arch Immunol Ther Exp (Warsz). (2018) 66:89–96. 10.1007/s00005-017-0491-5
    1. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. (2018) 9:7204–18. 10.18632/oncotarget.23208
    1. Ferreira VL, Borba HHL, Bonetti AF, Leonart LP, Pontarolo R. Cytokines and Interferons: Types and Functions. Autoantibodies and Cytokines. London: IntechOpen; (2019). 10.5772/intechopen.74550
    1. García-Martínez E, Smith M, Buqué A, Aranda F, Peña FA, Ivars A, et al. Trial watch: immunostimulation with recombinant cytokines for cancer therapy. Oncoimmunology. (2018) 7:e1433982. 10.1080/2162402X.2018.1433982
    1. McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, et al. The high-dose aldesleukin “select” trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res. (2015) 21:561–8. 10.1158/1078-0432.CCR-14-1520
    1. Eigentler TK, Gutzmer R, Hauschild A, Heinzerling L, Schadendorf D, Nashan D, et al. Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial. Ann Oncol. (2016) 27:1625–32. 10.1093/annonc/mdw225
    1. Habermann TM, Andersen JW, Cassileth PA, Bennett JM, Oken MM. Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemia. Br J Haematol. (1992) 80:466–71. 10.1111/j.1365-2141.1992.tb04559.x
    1. Lipton JH, Khoroshko N, Golenkov A, Abdulkadyrov K, Nair K, Raghunadharao D, et al. Phase II, randomized, multicenter, comparative study of peginterferon–α–2a (40 kD) (Pegasys®) versus interferon α-2a (Roferon®-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia. Leuk Lymphoma. (2007) 48:497–505. 10.1080/10428190601175393
    1. Biesma B, Willemse PHB, Mulder NH, Verschueren RCJ, Kema IP, de Bruijn HWA, et al. Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers. Br J Cancer. (1992) 66:850–5. 10.1038/bjc.1992.372
    1. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. (2001) 345:1655–9. 10.1056/NEJMoa003013
    1. Michallet M, Maloisel F, Delain M, Hellmann A, Rosas A, Silver RT, et al. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: A phase III study. Leukemia. (2004) 18:309–15. 10.1038/sj.leu.2403217
    1. Yamazaki N, Uhara H, Wada H, Matsuda K, Yamamoto K, Shimamoto T, et al. Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma. J Dermatol. (2016) 43:1146–53. 10.1111/1346-8138.13338

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe